Soliman Samar, Elsherbeny Mahmoud F, Sheta Heba, Mohamed Abdelaty Shawky, Fawzy Maha M, Sakr Doaa H, Lotfy Nadia
Oral Pathology, Faculty of Dentistry, Mansoura University, Mansoura, Egypt.
Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Pol J Pathol. 2022;73(4):320-329. doi: 10.5114/pjp.2022.125820.
Podoplanin (D2-40) is a lymphatic endothelial marker that is considered as a specific marker for lymphatic endothelial cells and lymphangiogenesis in salivary gland carcinomas (SGCs). Aim: the present study aimed to investigate the immunohistochemical expression of podoplanin in SGCs and to correlate its expression with the clinicopathological parameters and patients' survival. Forty-nine SGC cases were electronically selected. Demographic, clinical, laboratory, and survival data were reviewed and tabulated. Immunohistochemistry was performed using antipodoplanin. Cases were divided into low and high expression based on a scoring system. A score of 0 and 1 was considered low expression, while > 1 was considered high expression. Podoplanin high expression was seen in 46.9% of cases, and 53.1% of cases showed low expression. Significant statistical associations were seen between podoplanin expression and tumour grade ( p ≤ 0.001), tumour-nodal- metastasis (TNM) stage (p ≤ 0.001), tumour size (p ≤ 0.001), nodal metastasis (p ≤ 0.001), tumour type (p = 0.03), prognosis (p ≤ 0.001), and mortality (p ≤ 0.001). The overall survival and progression-free survival differed significantly in cases with high and low expression (p ≤ 0.001). Podoplanin overexpression might be a significant prognostic indicator for patients with SGCs, implicating that it is a potential therapeutic target to improve survival in these cancer patients.
血小板源性生长因子结合蛋白（D2-40）是一种淋巴管内皮标志物，被认为是唾液腺癌（SGC）中淋巴管内皮细胞和淋巴管生成的特异性标志物。目的：本研究旨在探讨血小板源性生长因子结合蛋白在唾液腺癌中的免疫组化表达，并将其表达与临床病理参数及患者生存率相关联。通过电子检索选取了49例唾液腺癌病例。对人口统计学、临床、实验室和生存数据进行回顾并列表。使用抗血小板源性生长因子结合蛋白进行免疫组化。根据评分系统将病例分为低表达和高表达。评分为0和1被认为是低表达，而>1被认为是高表达。46.9%的病例可见血小板源性生长因子结合蛋白高表达，53.1%的病例显示低表达。血小板源性生长因子结合蛋白表达与肿瘤分级（p≤0.001）、肿瘤-淋巴结-转移（TNM）分期（p≤0.001）、肿瘤大小（p≤0.001）、淋巴结转移（p≤0.001）、肿瘤类型（p = 0.03）、预后（p≤0.001）和死亡率（p≤0.001）之间存在显著的统计学关联。高表达和低表达病例的总生存期和无进展生存期有显著差异（p≤0.001）。血小板源性生长因子结合蛋白过表达可能是唾液腺癌患者的一个重要预后指标，这意味着它是改善这些癌症患者生存率的一个潜在治疗靶点。
